Related Experiment Videos
Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled
Oliver Freudenreich1, David C Henderson, Jared P Walsh
1Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., 2nd Floor, Boston, MA 02114, USA. ofreudenreich@partners.org
Rationale:
Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials.
Objectives:
To examine if adding risperidone to stable yet symptomatic schizophrenia outpatients on optimized clozapine monotherapy improves psychopathology.
Methods:
We conducted a double-blind placebo-controlled parallel-group trial of a fixed dose of 4 mg/day risperidone added for 6 weeks in 24 outpatients with schizophrenia.
Results:
Subjects who received risperidone showed a non-significant decrease in PANSS total score. The PANSS disorganized thought subscale improved significantly (beta=-3.3079, p=0.047).
Conclusions:
Our trial does not support the routine addition of risperidone to clozapine in refractory schizophrenia patients. However, much larger trials are needed to conclusively settle the question of added efficacy from this combination.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents
Antidepressant Drugs: MAOIs and Other Agents
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...